Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The validations confirm the completion of the applications and commence the scientific review process
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Sirius JV will be owned 51% by Sirius and 49% by Adani
Subscribe To Our Newsletter & Stay Updated
